Toceranib phosphate for treatment of hypercalcaemia of malignancy in two dogs with metastatic anal sac apocrine gland adenocarcinoma

This case series highlights two instances where toceranib monotherapy effectively managed hypercalcaemia of malignancy secondary to metastatic ASAGAC. Despite the presence of extensive macroscopic neoplastic disease, both dogs achieved durable control of hypercalcaemia with toceranib treatment.<b>Abbreviations:</b> ASAGAC: Anal sac apocrine gland adenocarcinoma; cRECIST: Canine response evaluation criteria in solid tumours; HHM: Humoral hypercalcaemia of malignancy; OST: Overall survival time; PFS: Progression-free survival; PTH: Parathyroid hormone; PTHrP: Parathyroid-related hormone peptide; RTK: Receptor tyrosine kinase; TKI: Tyrosine kinase inhibitor.